トランスサイレチンアミロイドーシスによる心不全患者に対するNNC6019-0001と呼ばれる薬剤の長期治療を検討する研究

基本情報

NCT ID

NCT06260709

ステータス

実施中（募集終了）

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

80

治験依頼者名

Novo Nordisk A/S

概要

This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study will be invited for this new study. Participants will get NNC6019-0001, regardless of whether they got placebo or NNC6019-0001 in the first study. The study will last for up to 157 weeks (36 months/3 years).

対象疾患

介入

依頼者（Sponsor）

実施施設 (6)